AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Verona Pharma PLC ADR (NASDAQ:VRNA)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 86 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 23.070/11.830 |
| EBITDA (in USD) | -72.503M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -0.80 |
| Total Assets (in USD) | 308.124M |
|---|---|
| Total Liabilities (in USD) | 58.841M |
| Revenue TTM (in USD) | 0.458M |
| Cash (in USD) | 271.772M |
| Market Cap (in USD) | 1,013.117 M |
| Revenue Per Share TTM | 0.006 |
| Gross Profit TTM (in USD) | 0.112M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Verona Pharma PLC ADR
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
3 More London Riverside, London, United Kingdom, SE1 2RE
44 20 3283 4200
Employees: 79
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. David S. Zaccardelli | Pres, CEO & Exec. Director | 1965 |
| 2. | Mr. Mark W. Hahn | Chief Financial Officer | 1963 |
| 3. | Dr. Kathleen A. Rickard | Chief Medical Officer | 1958 |
| 4. | Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA | Gen. Counsel | 1967 |
| 5. | Ms. Victoria Stewart | Director of Communications | NA |
| 6. | Mr. Matthew Casbon | VP of Sales, Marketing & Training | NA |
| 7. | Ms. Ostra Jewell | Sr. VP of HR | NA |
| 8. | Dr. Peter Spargo | Sr. VP of Chemistry Manufacturing & Controls | 1962 |
| 9. | Dr. Tara Rheault M.P.H., Ph.D. | Sr. VP of R&D | 1977 |
| 10. | Ms. Nina Church | Exec. Director of Global Clinical Devel. | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.165 0.376% | 44.03 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.001 0.003% | 44.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.210 0.491% | 452.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.570 0.093% | 615.18 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -68.448M | -55.587M | -65M | -51.406M | -30.623M |
| Minority Interest | - | - | - | 0M | 0M |
| Net Income | -68.701M | -55.569M | -65.146M | -41.88M | -25.253M |
| Selling General Administrative | 26.579M | 33.907M | 29.772M | 8.995M | 7.985M |
| Gross Profit | 0.112M | 40M | 0.002M | 0.002M | 0.003M |
| Reconciled Depreciation | 0.636M | 0.629M | 0.623M | 0.661M | 0.124M |
| Ebit | -66.116M | -73.313M | -74.277M | -53.867M | -31.391M |
| Ebitda | -62.659M | -57.04M | -65.266M | -51.765M | -31.267M |
| Depreciation And Amortization | 3.457M | 16.273M | 9.011M | 2.102M | 0.124M |
| Operating Income | -66.116M | -73.313M | -74.277M | -53.867M | -32.473M |
| Other Operating Expenses | 66.574M | 97.683M | 66.01M | 53.414M | 32.484M |
| Interest Expense | 0.521M | 0.34M | 0.035M | 0.222M | 0.135M |
| Tax Provision | 0.253M | -0.018M | 0.146M | -7.265M | -4.232M |
| Interest Income | 2.821M | 0.014M | 0.121M | 0.754M | 0.861M |
| Net Interest Income | 2.3M | -0.326M | 0.086M | 0.585M | 0.755M |
| Income Tax Expense | 0.253M | -0.018M | 0.146M | -9.526M | -5.37M |
| Total Revenue | 0.458M | 40M | 0.002M | 0.002M | 0.003M |
| Total Operating Expenses | 66.228M | 97.683M | 66.01M | 53.414M | 32.484M |
| Cost Of Revenue | 0.346M | - | - | 0M | 0M |
| Total Other Income Expense Net | -2.332M | 17.726M | 9.277M | 2.461M | 1.85M |
| Net Income From Continuing Ops | -68.701M | -55.569M | -65.146M | -31.941M | -19.901M |
| Net Income Applicable To Common Shares | -68.701M | -55.569M | -65.146M | -40.561M | -19.901M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 308.124M | 259.468M | 186.587M | 204.206M | 59.179M |
| Intangible Assets | - | - | - | 3.615M | 3.615M |
| Other Current Assets | 6.982M | 3.388M | 2.063M | 1.72M | 0.01M |
| Total Liab | 58.841M | 29.002M | 38.582M | 19.352M | 14.777M |
| Total Stockholder Equity | 249.283M | 230.466M | 148.005M | 184.854M | 44.403M |
| Other Current Liab | 4.02M | 15.444M | 0.327M | 2.364M | 10.097M |
| Common Stock | 42.771M | 40.526M | 31.855M | 31.794M | 6.905M |
| Capital Stock | 42.771M | 40.526M | 31.855M | 31.794M | 6.905M |
| Retained Earnings | -388.433M | -333.097M | -263.716M | -207.05M | -131.939M |
| Good Will | 0.545M | 0.545M | 0.545M | 0.545M | 0.578M |
| Other Assets | 0M | - | - | 1.157M | 0M |
| Cash | 271.772M | 227.827M | 148.38M | 187.986M | 30.07M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 8.692M | 19.029M | 33.422M | 14.203M | 12.608M |
| Current Deferred Revenue | 0M | - | 22.403M | 10.863M | 0M |
| Net Debt | -220.443M | -217.179M | -142.572M | -182.039M | -28.823M |
| Short Term Debt | 1.18M | 0.675M | 0.648M | 0.798M | 0.603M |
| Short Long Term Debt | - | - | - | - | 0M |
| Short Long Term Debt Total | 51.329M | 10.648M | 5.808M | 5.947M | 1.247M |
| Other Stockholder Equity | 599.546M | 527.638M | 384.467M | 364.711M | 169.437M |
| Property Plant Equipment | - | 0.927M | 0.979M | 1.157M | 1.351M |
| Total Current Assets | 289.708M | 242.996M | 170.063M | 202.504M | 53.657M |
| Long Term Investments | 15M | 15M | 15M | - | 0M |
| Short Term Investments | - | - | - | 10.257M | 10.257M |
| Net Receivables | 10.954M | 9.282M | 15.583M | 8.26M | 9.814M |
| Long Term Debt | 48.374M | 9.768M | 4.874M | 4.635M | 0M |
| Inventory | 0M | 2.499M | 4.037M | 4.538M | 0M |
| Accounts Payable | 3.492M | 2.91M | 10.044M | 0.178M | 1.908M |
| Accumulated Other Comprehensive Income | -4.601M | -4.601M | -4.601M | -4.601M | 0M |
| Non Currrent Assets Other | 15.024M | 15.073M | 15.08M | - | 0.971M |
| Non Current Assets Total | 18.416M | 16.472M | 16.524M | 1.702M | 5.523M |
| Capital Lease Obligations | 2.955M | 0.88M | 0.934M | 1.312M | 0.951M |
| Long Term Debt Total | - | - | - | - | 0.491M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.029M | -0.012M | 9.71M | 37.799M | 5.281M |
| Total Cashflows From Investing Activities | -0.029M | -0.012M | 9.71M | 47.314M | 5.281M |
| Total Cash From Financing Activities | 140.818M | -6.117M | 192.343M | -0.559M | -3.816M |
| Net Income | -68.701M | -55.569M | -65.146M | -51.406M | -30.623M |
| Change In Cash | 79.447M | -39.606M | 157.558M | 4.13M | -14.794M |
| Begin Period Cash Flow | 148.38M | 187.986M | 30.428M | 25.94M | 39.898M |
| End Period Cash Flow | 227.827M | 148.38M | 187.986M | 30.07M | 25.104M |
| Total Cash From Operating Activities | -59.862M | -33.254M | -45.076M | -44.344M | -22.981M |
| Depreciation | 0.636M | 0.629M | 0.623M | 0.661M | 0.124M |
| Other Cashflows From Investing Activities | - | - | - | 0.887M | 0.883M |
| Dividends Paid | - | - | - | 0M | 0M |
| Change To Inventory | - | - | - | 0M | 0M |
| Sale Purchase Of Stock | - | - | - | 0M | 0M |
| Other Cashflows From Financing Activities | -3.979M | -6.85M | -7.813M | -0.558M | 6.701M |
| Capital Expenditures | 0.029M | 0.012M | 0.082M | 0.37M | 0.34M |
| Change In Working Capital | -10.738M | 13.444M | -2.113M | -0.046M | -0.138M |
| Other Non Cash Items | 4.82M | 0.239M | 0.018M | -2.461M | -1.85M |
| Free Cash Flow | -59.891M | -33.266M | -45.158M | -44.713M | -23.321M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Eventide Healthcare & Life Sciences I | 2 years ago | 1377781 |
| 2. | Vanguard Health Care Inv | 2 years ago | 1160032 |
| 3. | Federated Hermes Kaufmann R | 2 years ago | 1145000 |
| 4. | Federated Hermes Kaufmann Growth | 2 years ago | 1145000 |
| 5. | Federated Hermes Kaufmann Small Cap Grow | 2 years ago | 1085000 |
| 6. | Federated Hermes Kaufmann Small Cap A | 2 years ago | 1085000 |
| 7. | Fidelity Select Biotechnology | 2 years ago | 809101 |
| 8. | Bellevue Healthcare Ord | 2 years ago | 777297 |
| 9. | Jennison Health Sciences Equity | 2 years ago | 699240 |
| 10. | PGIM Jennison Health Sciences Z | 2 years ago | 699240 |
| 11. | Fidelity Small Cap Growth | 2 years ago | 660386 |
| 12. | FIAM Small Cap Core CIT Cl B | 2 years ago | 559700 |
| 13. | Janus Henderson Venture D | 2 years ago | 492127 |
| 14. | Janus Henderson US Small Cap Growth | 2 years ago | 492127 |
| 15. | American Century Small Cap Growth Inv | 2 years ago | 486547 |
| 16. | American Century U.S. Small Cap Growth | 2 years ago | 486547 |
| 17. | Hood River Small-Cap Growth Instl | 2 years ago | 476765 |
| 18. | Wellington Global Hlthcr Eq USD G Ac | 2 years ago | 447357 |
| 19. | FIAM Small Cap Core Composite | 2 years ago | 433600 |
| 20. | SEB Läkemedelsfond | 2 years ago | 409006 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 2 years ago | 6317990 |
| 2. | NEA Management Company, LLC | 2 years ago | 5108563 |
| 3. | FMR Inc | 2 years ago | 4902377 |
| 4. | Wellington Management Company LLP | 2 years ago | 3783994 |
| 5. | Perceptive Advisors LLC | 2 years ago | 3761576 |
| 6. | Vivo Capital, LLC | 2 years ago | 3610177 |
| 7. | Orbimed Advisors, LLC | 2 years ago | 3398067 |
| 8. | Deep Track Capital, LP | 2 years ago | 3187415 |
| 9. | The Carlyle Group Inc | 2 years ago | 2457500 |
| 10. | Octagon Capital Advisors LP | 2 years ago | 2369000 |
| 11. | Federated Hermes Inc | 2 years ago | 2258600 |
| 12. | Eventide Asset Management, LLC | 2 years ago | 2187520 |
| 13. | HHG PLC | 2 years ago | 2031994 |
| 14. | Maverick Capital Ltd | 2 years ago | 1775809 |
| 15. | Jennison Associates LLC | 2 years ago | 1593833 |
| 16. | Caligan Partners LP | 2 years ago | 1296447 |
| 17. | Bellevue Group AG | 2 years ago | 1139295 |
| 18. | Aisling Capital Management LP | 2 years ago | 1115352 |
| 19. | Hood River Capital Management LLC | 2 years ago | 987756 |
| 20. | First Turn Management LLC | 2 years ago | 973130 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...